RLYB

Company Overview — What Does Rallybio Corp Do?

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corp (RLYB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Martin W. MacKay and employs approximately 40 people. With a market capitalization of $44M, RLYB is one of the notable companies in the Healthcare sector.

Rallybio Corp (RLYB) Stock Rating — Reduce (April 2026)

As of April 2026, Rallybio Corp receives a Reduce rating with a composite score of 37.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RLYB ranks #1,997 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Rallybio Corp ranks #214 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

RLYB Stock Price and 52-Week Range

Rallybio Corp (RLYB) currently trades at $8.21. The 52-week high for RLYB is $11.49, which means the stock is currently trading -28.5% from its annual peak. The 52-week low is $0.22, putting the stock 3630.1% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is RLYB Overvalued or Undervalued? — Valuation Analysis

Rallybio Corp (RLYB) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 26.67x, compared to the Healthcare sector average of 23.63x — a premium of 13%. The price-to-book ratio stands at 0.73x, versus the sector average of 2.75x. The price-to-sales ratio is 45.54x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, RLYB trades at 0.34x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Rallybio Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Rallybio Corp Profitability — ROE, Margins, and Quality Score

Rallybio Corp (RLYB) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -25.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.4% versus the sector average of -33.1%.

On a margin basis, Rallybio Corp reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -4151.8% (sector: -66.1%). Net profit margin stands at -1327.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -29.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

RLYB Debt, Balance Sheet, and Financial Health

Rallybio Corp has a debt-to-equity ratio of 7.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.50x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $32M.

RLYB has a beta of 4.46, meaning it is more volatile than the broader market — a $10,000 investment in RLYB would be expected to move 345.5% more than the S&P 500 on any given day. The stability factor score for Rallybio Corp is 11/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Rallybio Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Rallybio Corp reported revenue of $935,000 and earnings per share (EPS) of $-1.59. Net income for the quarter was $-15M. Gross margin was 100.0%. Operating income came in at $-39M.

In FY 2025, Rallybio Corp reported revenue of $858,000 and earnings per share (EPS) of $-1.59. Net income for the quarter was $-9M. Revenue grew 43.0% year-over-year compared to FY 2024. Operating income came in at $-33M.

In Q3 2025, Rallybio Corp reported revenue of $212,000 and earnings per share (EPS) of $0.36. Net income for the quarter was $16M. Revenue grew -29.1% year-over-year compared to Q3 2024. Operating income came in at $-7M.

In Q2 2025, Rallybio Corp reported revenue of $212,000 and earnings per share (EPS) of $-0.22. Net income for the quarter was $-10M. Revenue grew -29.1% year-over-year compared to Q2 2024. Operating income came in at $-10M.

Over the past 8 quarters, Rallybio Corp has demonstrated a growth trajectory, with revenue expanding from $299,000 to $935,000. Investors analyzing RLYB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

RLYB Dividend Yield and Income Analysis

Rallybio Corp (RLYB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

RLYB Momentum and Technical Analysis Profile

Rallybio Corp (RLYB) has a momentum factor score of 81/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 36/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

RLYB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Rallybio Corp (RLYB) ranks #214 out of 838 stocks based on the Blank Capital composite score. This places RLYB in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing RLYB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RLYB vs S&P 500 (SPY) comparison to assess how Rallybio Corp stacks up against the broader market across all factor dimensions.

RLYB Next Earnings Date

No upcoming earnings date has been announced for Rallybio Corp (RLYB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy RLYB? — Investment Thesis Summary

The quantitative profile for Rallybio Corp suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 81/100, suggesting the trend favors buyers. High volatility (stability score 11/100) increases portfolio risk.

In summary, Rallybio Corp (RLYB) earns a Reduce rating with a composite score of 37.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RLYB stock.

Related Resources for RLYB Investors

Explore more research and tools: RLYB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RLYB head-to-head with peers: RLYB vs AZN, RLYB vs SLGL, RLYB vs VMD.